Sugi Predict

Sugi Predict / Compounds / SCHEMBL3759271

SCHEMBL3759271

SCHEMBL3759271

N#Cc1cccc(-n2ncc3c(NCC(=O)O)ncnc32)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 10/20 0.61
▸ SLC2A1 P11166 1/20 0.56
▸ SLC2A2 P11168 1/20 0.56
▸ SLC2A3 P11169 1/20 0.56
▸ KDM4E B2RXH2 9/20 0.54
▸ HSD17B10 Q99714 5/20 0.54
▸ TSHR P16473 3/20 0.54
▸ MAPK10 P53779 1/20 0.54
▸ SMN1; SMN2 Q16637 7/20 0.53
▸ NPC1 O15118 7/20 0.53
▸ RAB9A P51151 7/20 0.53
▸ LMNA P02545 6/20 0.52
▸ ALDH1A1 P00352 8/20 0.52
▸ HPGD P15428 6/20 0.52
▸ NPSR1 Q6W5P4 2/20 0.52
▸ NFKB1 P19838 2/20 0.52
▸ NFKB2 Q00653 2/20 0.52
▸ RELA Q04206 2/20 0.52
▸ CASP3 P42574 1/20 0.52
▸ SENP8 Q96LD8 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13058188 0.90 KDM4E (0.54) MAPTKDM4EHSD17B10TSHRMAPK10
SCHEMBL13058207 0.86 KDM4E (0.51) MAPTKDM4EHSD17B10TSHRMAPK10
SCHEMBL3748954 0.84 KDM4E (0.72) MAPTKDM4EHSD17B10TSHRMAPK10
SCHEMBL13058215 0.84 KDM4E (0.57) MAPTKDM4EHSD17B10TSHRMAPK10
SCHEMBL3761422 0.78 MAPT (0.69) MAPTKDM4EHSD17B10TSHRMAPK10
SCHEMBL13058220 0.78 TP53 (0.62) MAPTSLC2A1SLC2A3KDM4EHSD17B10
SCHEMBL3761467 0.77 KDM4E (0.56) MAPTKDM4EHSD17B10TSHRMAPK10
SCHEMBL13058221 0.76 KDM4E (0.55) MAPTSLC2A1SLC2A3KDM4EHSD17B10
SCHEMBL3399024 0.76 KDM4E (0.55) MAPTSLC2A1SLC2A3KDM4EHSD17B10
SCHEMBL3759157 0.76 MAPT (0.58) MAPTKDM4EHSD17B10TSHRMAPK10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8349847-B2 Pyrazolo [3,4-D] pyrimidine derivatives as anti-cancer agents KONAKANCHI DURGA PRASAD (IN) 2013-01-08 — — US disclosed
US-8349847-B2 Pyrazolo [3,4-D] pyrimidine derivatives as anti-cancer agents KONAKANCHI DURGA PRASAD (IN) 2013-01-08 — — US disclosed
US-8349847-B2 Pyrazolo [3,4-D] pyrimidine derivatives as anti-cancer agents KONAKANCHI DURGA PRASAD (IN) 2013-01-08 — — US disclosed
US-20100298351-A1 NOVEL PYRAZOLO [3, 4 -D] PYRIMIDINE DERIVATIVES AS ANTI-CANCER AGENTS NATCO PHARMA LIMITED (IN) 2010-11-25 — — US disclosed
US-20100298351-A1 NOVEL PYRAZOLO [3, 4 -D] PYRIMIDINE DERIVATIVES AS ANTI-CANCER AGENTS NATCO PHARMA LIMITED (IN) 2010-11-25 — — US disclosed
US-20100298351-A1 NOVEL PYRAZOLO [3, 4 -D] PYRIMIDINE DERIVATIVES AS ANTI-CANCER AGENTS NATCO PHARMA LIMITED (IN) 2010-11-25 — — US disclosed
WO-2009098715-A2 NOVEL PYRAZOLO [3, 4 -D] PYRIMIDINE DERIVATIVES AS ANTI -CANCER AGENTS NATCO PHARMA LIMITED (IN) 2009-08-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298351-A1 NOVEL PYRAZOLO [3, 4 -D] PYRIMIDINE DERIVATIVES AS ANTI-CANCER AGENTS DPYD, TYMP, TYMS MAPT 3730/4885SLC2A1 2893/4885SLC2A2 3224/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.